title: In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
abstract: Iguratimod is a novel disease-modifying antirheumatic drug. A blue letter (safety advisory) for drug interaction between iguratimod and warfarin was issued by the Ministry of Health, Labour and Welfare of Japan in May 2013. Iguratimod may affect warfarin metabolism catalyzed by CYP. However, it is not clear whether iguratimod inhibits warfarin oxidation. This study was performed to investigate the effects of iguratimod on warfarin 7-hydroxylation with human liver microsomes (HLMs) and recombinant CYP enzymes. Iguratimod concentration-dependently inhibited R,S-warfarin 7-hydroxylase activity of HLMs with an IC50 value of 15.2 µM. The inhibitory effect was examined with S-warfarin and R-warfarin to determine which enantiomer was more potently inhibited by iguratimod. Iguratimod potently inhibited the S-warfarin 7-hydroxylase activity of HLMs with an IC50 value of 14.1 µM, but showed only slight inhibition of R-warfarin 7-hydroxylation. Furthermore, iguratimod inhibited the S-warfarin 7-hydroxylase activity of recombinant CYP2C9.1 (rCYP2C9.1) and rCYP2C9.3 in a concentration-dependent manner with IC50 values of 10.8 and 20.1 µM, respectively. Kinetic analysis of the inhibition of S-warfarin 7-hydroxylation by iguratimod indicated competitive-type inhibition for HLMs and rCYP2C9.1 but mixed-type inhibition for rCYP2C9.3. The Ki values for HLMs, rCYP2C9.1, and rCYP2C9.3 were 6.74, 4.23, and 14.2 µM, respectively. Iguratimod did not exert metabolism-dependent inhibition of S-warfarin 7-hydroxylation. These results indicated that iguratimod is a potent direct inhibitor of CYP2C9-mediated warfarin 7-hydroxylation and that its inhibitory effect on CYP2C9.1 was more sensitive than that on CYP2C9.3.
authors.affiliation: Department of Pharmacy, Shinshu University Hospital, 3-1-1;Department of Biochemical Pharmacology and Toxicology, Graduate School of Medicine, Shinshu University 390-8621, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaori
authors.forename: Ken
authors.initials: K
authors.lastname: Takami
authors.forename: Ayaka
authors.initials: A
authors.lastname: Shiozawa
authors.forename: Kanako
authors.initials: K
authors.lastname: Sakuyama
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsuzawa
authors.forename: Shigeru
authors.initials: S
authors.lastname: Ohmori
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000494:pharmacology; D002867:Chromones / Q000494:pharmacology*; D065729:Cytochrome P-450 CYP2C9 / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D006900:Hydroxylation; D007166:Immunosuppressive Agents / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D013237:Stereoisomerism; D013449:Sulfonamides / Q000494:pharmacology*; D014859:Warfarin / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D018501:Antirheumatic Agents; D002867:Chromones; D007166:Immunosuppressive Agents; D013449:Sulfonamides; C519076:iguratimod; D014859:Warfarin; D065729:Cytochrome P-450 CYP2C9